Share Price and Basic Stock Data
Last Updated: December 25, 2025, 3:48 am
| PEG Ratio | 1.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Unichem Laboratories Ltd, a prominent player in the pharmaceuticals sector, reported a market capitalization of ₹3,167 Cr and a current price of ₹449 per share. The company recorded a revenue from operations of ₹2,226 Cr in the trailing twelve months (TTM), reflecting a significant increase from ₹2,111 Cr in FY 2025. Historically, Unichem’s sales have shown variability, with a peak annual revenue of ₹1,785 Cr in FY 2024 and a notable recovery trend post-pandemic, as evidenced by quarterly sales of ₹466 Cr in December 2023 and ₹483 Cr in June 2024. This upward trajectory highlights the company’s ability to adapt and capture market opportunities. However, the company also faced challenges in earlier quarters, with a decline in sales in December 2022 (₹302 Cr) and a subsequent recovery. The consistent growth in sales over recent quarters suggests a potential stabilization and improved market demand for Unichem’s products.
Profitability and Efficiency Metrics
Unichem Laboratories’ profitability metrics indicate a challenging environment, with a reported net profit of ₹88 Cr for TTM, an improvement from a net loss of ₹202 Cr in FY 2023. The operating profit margin (OPM) stood at 12.56%, reflecting a recovery from previous years’ fluctuations. The company reported an OPM of 4% in FY 2022 and a decline to -3% in FY 2023, but improved to 14.22% in FY 2025. The return on equity (ROE) is currently at 5.59%, which is below the industry average, indicating room for improvement in capital efficiency. The interest coverage ratio (ICR) of 14.27x indicates a strong capacity to cover interest expenses, reflecting financial stability. However, the company’s cash conversion cycle (CCC) of 382 days suggests inefficiencies in managing receivables and inventories, which could impact liquidity and operational efficiency if not addressed.
Balance Sheet Strength and Financial Ratios
Unichem’s balance sheet reflects a solid foundation with total reserves of ₹2,421 Cr and borrowings amounting to ₹502 Cr, resulting in a low long-term debt to equity ratio of 0.02. This indicates prudent financial management and lower financial risk compared to industry norms. The company’s current ratio of 2.05 and quick ratio of 1.06 suggest adequate liquidity to meet short-term obligations. However, the price-to-book value ratio (P/BV) of 1.99x indicates that the stock is trading at a premium relative to its book value, which could be a concern for value-oriented investors. The overall financial ratios reveal a mixed picture; while the company has maintained a strong asset base with total assets of ₹3,569 Cr, the return on capital employed (ROCE) of 6.81% is modest and highlights the need for improved capital utilization to enhance overall profitability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Unichem Laboratories indicates a significant promoter holding of 70.22%, which reflects strong insider confidence in the company’s future. Foreign institutional investors (FIIs) hold 0.99%, while domestic institutional investors (DIIs) account for 10.74%. The public shareholding stands at 18.04%, with a total of 23,577 shareholders as of the latest reporting period. Notably, the decline in public shareholding from 39.31% in December 2022 to 18.04% in December 2024 may raise concerns about liquidity and market perception. The increase in promoter stake from 50.94% in December 2022 to the current level suggests confidence in the company’s strategy and future performance. However, the low FII participation could indicate caution among foreign investors regarding the company’s growth prospects, reflecting a need for improved transparency and communication from management to bolster investor confidence.
Outlook, Risks, and Final Insight
Looking ahead, Unichem Laboratories faces a mixed outlook characterized by both opportunities and risks. On the positive side, the company’s ability to enhance its profitability and achieve consistent revenue growth could attract further investment and bolster its market position. The strong ICR and low debt levels provide a cushion against financial distress. However, risks include the high cash conversion cycle, which may hinder liquidity and operational flexibility, and the modest ROE, which could lead to investor skepticism. Additionally, increasing competition in the pharmaceuticals sector and regulatory challenges could impact future growth. Therefore, while Unichem has the potential for recovery and growth, it must address operational inefficiencies and enhance transparency to reassure investors and capitalize on market opportunities effectively.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 135 Cr. | 107 | 231/84.3 | 29.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,770 Cr. | 438 | 479/192 | 98.8 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.7 Cr. | 33.3 | 35.0/17.0 | 116 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,181.97 Cr | 1,153.40 | 53.07 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 310 | 329 | 302 | 402 | 423 | 416 | 466 | 432 | 483 | 507 | 533 | 587 | 527 |
| Expenses | 311 | 347 | 345 | 386 | 395 | 407 | 435 | 406 | 443 | 452 | 448 | 503 | 504 |
| Operating Profit | -1 | -18 | -43 | 16 | 28 | 9 | 31 | 25 | 40 | 55 | 86 | 84 | 22 |
| OPM % | -0% | -6% | -14% | 4% | 7% | 2% | 7% | 6% | 8% | 11% | 16% | 14% | 4% |
| Other Income | 8 | 4 | 16 | -28 | 9 | 6 | 79 | -119 | 4 | 9 | 14 | 9 | 7 |
| Interest | 3 | 5 | 4 | 6 | 6 | 7 | 6 | 5 | 4 | 5 | 7 | 5 | 7 |
| Depreciation | 25 | 28 | 31 | 30 | 29 | 29 | 32 | 27 | 32 | 32 | 31 | 30 | 32 |
| Profit before tax | -21 | -47 | -61 | -47 | 2 | -22 | 73 | -126 | 8 | 27 | 62 | 58 | -9 |
| Tax % | 13% | 50% | 4% | -6% | 132% | 12% | -0% | 3% | 74% | 9% | 6% | 8% | 16% |
| Net Profit | -23 | -71 | -64 | -44 | -1 | -24 | 73 | -129 | 2 | 25 | 58 | 53 | -10 |
| EPS in Rs | -3.32 | -10.04 | -9.08 | -6.29 | -0.10 | -3.48 | 10.40 | -18.37 | 0.29 | 3.50 | 8.22 | 7.52 | -1.49 |
Last Updated: August 20, 2025, 1:50 am
Below is a detailed analysis of the quarterly data for Unichem Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 527.00 Cr.. The value appears to be declining and may need further review. It has decreased from 587.00 Cr. (Mar 2025) to 527.00 Cr., marking a decrease of 60.00 Cr..
- For Expenses, as of Jun 2025, the value is 504.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 503.00 Cr. (Mar 2025) to 504.00 Cr., marking an increase of 1.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 84.00 Cr. (Mar 2025) to 22.00 Cr., marking a decrease of 62.00 Cr..
- For OPM %, as of Jun 2025, the value is 4.00%. The value appears to be declining and may need further review. It has decreased from 14.00% (Mar 2025) to 4.00%, marking a decrease of 10.00%.
- For Other Income, as of Jun 2025, the value is 7.00 Cr.. The value appears to be declining and may need further review. It has decreased from 9.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 2.00 Cr..
- For Interest, as of Jun 2025, the value is 7.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Jun 2025, the value is 32.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 30.00 Cr. (Mar 2025) to 32.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -9.00 Cr.. The value appears to be declining and may need further review. It has decreased from 58.00 Cr. (Mar 2025) to -9.00 Cr., marking a decrease of 67.00 Cr..
- For Tax %, as of Jun 2025, the value is 16.00%. The value appears to be increasing, which may not be favorable. It has increased from 8.00% (Mar 2025) to 16.00%, marking an increase of 8.00%.
- For Net Profit, as of Jun 2025, the value is -10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 53.00 Cr. (Mar 2025) to -10.00 Cr., marking a decrease of 63.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -1.49. The value appears to be declining and may need further review. It has decreased from 7.52 (Mar 2025) to -1.49, marking a decrease of 9.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:27 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,133 | 1,202 | 1,333 | 698 | 815 | 1,180 | 1,104 | 1,235 | 1,270 | 1,343 | 1,785 | 2,111 | 2,226 |
| Expenses | 956 | 1,100 | 1,169 | 738 | 942 | 1,254 | 1,153 | 1,144 | 1,198 | 1,389 | 1,698 | 1,846 | 1,968 |
| Operating Profit | 178 | 101 | 164 | -41 | -128 | -74 | -49 | 91 | 72 | -46 | 87 | 265 | 258 |
| OPM % | 16% | 8% | 12% | -6% | -16% | -6% | -4% | 7% | 6% | -3% | 5% | 13% | 12% |
| Other Income | 83 | 20 | 15 | 184 | 2,735 | 91 | 91 | 50 | 47 | -0 | -26 | 35 | -8 |
| Interest | 3 | 3 | 3 | 3 | 8 | 8 | 8 | 5 | 6 | 17 | 23 | 21 | 27 |
| Depreciation | 46 | 41 | 39 | 44 | 51 | 67 | 82 | 84 | 91 | 113 | 123 | 125 | 123 |
| Profit before tax | 212 | 77 | 137 | 97 | 2,548 | -58 | -48 | 51 | 22 | -176 | -85 | 155 | 100 |
| Tax % | 20% | 3% | 21% | -12% | 0% | -59% | 25% | 33% | -50% | 15% | 10% | 11% | |
| Net Profit | 169 | 75 | 108 | 109 | 2,545 | -24 | -60 | 34 | 33 | -202 | -94 | 138 | 88 |
| EPS in Rs | 18.68 | 8.31 | 11.90 | 11.96 | 361.82 | -3.38 | -8.55 | 4.87 | 4.70 | -28.72 | -13.32 | 19.53 | 12.56 |
| Dividend Payout % | 43% | 24% | 17% | 25% | 1% | -118% | -47% | 82% | 85% | -14% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -55.62% | 44.00% | 0.93% | 2234.86% | -100.94% | -150.00% | 156.67% | -2.94% | -712.12% | 53.47% | 246.81% |
| Change in YoY Net Profit Growth (%) | 0.00% | 99.62% | -43.07% | 2233.94% | -2335.81% | -49.06% | 306.67% | -159.61% | -709.18% | 765.59% | 193.34% |
Unichem Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 14% |
| 3 Years: | 18% |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 29% |
| 3 Years: | 63% |
| TTM: | 651% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 15% |
| 3 Years: | 12% |
| 1 Year: | -13% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 0% |
| 3 Years: | -1% |
| Last Year: | 6% |
Last Updated: September 5, 2025, 1:50 pm
Balance Sheet
Last Updated: December 4, 2025, 2:09 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18 | 18 | 18 | 18 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 798 | 849 | 936 | 1,045 | 2,666 | 2,606 | 2,517 | 2,543 | 2,604 | 2,421 | 2,424 | 2,437 | 2,421 |
| Borrowings | 26 | 22 | 36 | 98 | 151 | 200 | 206 | 119 | 349 | 314 | 248 | 460 | 502 |
| Other Liabilities | 302 | 264 | 283 | 359 | 359 | 323 | 407 | 436 | 351 | 444 | 589 | 659 | 619 |
| Total Liabilities | 1,145 | 1,153 | 1,274 | 1,521 | 3,190 | 3,142 | 3,145 | 3,112 | 3,319 | 3,193 | 3,275 | 3,569 | 3,556 |
| Fixed Assets | 419 | 416 | 403 | 491 | 578 | 810 | 870 | 884 | 990 | 1,257 | 1,252 | 1,300 | 1,246 |
| CWIP | 91 | 123 | 237 | 250 | 238 | 92 | 330 | 568 | 494 | 147 | 123 | 31 | 79 |
| Investments | 11 | 41 | 14 | 14 | 901 | 926 | 550 | 392 | 264 | 2 | 1 | 0 | 0 |
| Other Assets | 623 | 574 | 620 | 766 | 1,473 | 1,313 | 1,395 | 1,269 | 1,571 | 1,787 | 1,898 | 2,239 | 2,231 |
| Total Assets | 1,145 | 1,153 | 1,274 | 1,521 | 3,190 | 3,142 | 3,145 | 3,112 | 3,319 | 3,193 | 3,275 | 3,569 | 3,556 |
Below is a detailed analysis of the balance sheet data for Unichem Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 14.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,421.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,437.00 Cr. (Mar 2025) to 2,421.00 Cr., marking a decrease of 16.00 Cr..
- For Borrowings, as of Sep 2025, the value is 502.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 460.00 Cr. (Mar 2025) to 502.00 Cr., marking an increase of 42.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 619.00 Cr.. The value appears to be improving (decreasing). It has decreased from 659.00 Cr. (Mar 2025) to 619.00 Cr., marking a decrease of 40.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 3,556.00 Cr.. The value appears to be improving (decreasing). It has decreased from 3,569.00 Cr. (Mar 2025) to 3,556.00 Cr., marking a decrease of 13.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,246.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,300.00 Cr. (Mar 2025) to 1,246.00 Cr., marking a decrease of 54.00 Cr..
- For CWIP, as of Sep 2025, the value is 79.00 Cr.. The value appears strong and on an upward trend. It has increased from 31.00 Cr. (Mar 2025) to 79.00 Cr., marking an increase of 48.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,231.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,239.00 Cr. (Mar 2025) to 2,231.00 Cr., marking a decrease of 8.00 Cr..
- For Total Assets, as of Sep 2025, the value is 3,556.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,569.00 Cr. (Mar 2025) to 3,556.00 Cr., marking a decrease of 13.00 Cr..
Notably, the Reserves (2,421.00 Cr.) exceed the Borrowings (502.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 152.00 | 79.00 | 128.00 | -139.00 | -279.00 | -274.00 | -255.00 | -28.00 | -277.00 | -360.00 | -161.00 | -195.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 63 | 58 | 60 | 165 | 124 | 135 | 129 | 74 | 142 | 160 | 131 | 135 |
| Inventory Days | 192 | 171 | 184 | 397 | 278 | 278 | 374 | 518 | 527 | 414 | 365 | 418 |
| Days Payable | 142 | 114 | 131 | 297 | 230 | 182 | 236 | 202 | 161 | 193 | 174 | 170 |
| Cash Conversion Cycle | 113 | 116 | 113 | 265 | 172 | 231 | 267 | 390 | 508 | 382 | 322 | 382 |
| Working Capital Days | 94 | 88 | 90 | 174 | 133 | 165 | 154 | 163 | 207 | 207 | 173 | 159 |
| ROCE % | 19% | 9% | 15% | 9% | 128% | -2% | -2% | 2% | 1% | -5% | -0% | 6% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Small Cap Fund | 5,458,645 | 0.67 | 255 | N/A | N/A | N/A |
| DSP Healthcare Fund | 852,063 | 1.25 | 39.8 | 735,591 | 2025-11-03 09:45:15 | 15.83% |
| Quant Value Fund | 147,732 | 0.4 | 6.9 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 19.53 | -10.01 | -28.72 | 4.70 | 4.88 |
| Diluted EPS (Rs.) | 19.53 | -10.01 | -28.72 | 4.70 | 4.88 |
| Cash EPS (Rs.) | 37.23 | 6.07 | -7.13 | 17.80 | 16.91 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 348.10 | 335.54 | 345.89 | 371.90 | 363.16 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 348.10 | 335.54 | 345.89 | 371.90 | 363.16 |
| Revenue From Operations / Share (Rs.) | 299.85 | 242.15 | 190.75 | 180.36 | 175.43 |
| PBDIT / Share (Rs.) | 42.64 | 18.73 | -0.99 | 17.09 | 20.07 |
| PBIT / Share (Rs.) | 24.95 | 2.64 | -17.11 | 4.14 | 8.09 |
| PBT / Share (Rs.) | 21.96 | -8.76 | -19.57 | 3.27 | 7.36 |
| Net Profit / Share (Rs.) | 19.53 | -10.01 | -23.25 | 4.85 | 4.92 |
| NP After MI And SOA / Share (Rs.) | 19.53 | -10.01 | -28.72 | 4.70 | 4.88 |
| PBDIT Margin (%) | 14.22 | 7.73 | -0.52 | 9.47 | 11.43 |
| PBIT Margin (%) | 8.31 | 1.09 | -8.97 | 2.29 | 4.61 |
| PBT Margin (%) | 7.32 | -3.61 | -10.26 | 1.81 | 4.19 |
| Net Profit Margin (%) | 6.51 | -4.13 | -12.18 | 2.68 | 2.80 |
| NP After MI And SOA Margin (%) | 6.51 | -4.13 | -15.05 | 2.60 | 2.77 |
| Return on Networth / Equity (%) | 5.61 | -2.98 | -8.30 | 1.26 | 1.34 |
| Return on Capital Employeed (%) | 6.81 | 0.75 | -4.71 | 1.05 | 2.17 |
| Return On Assets (%) | 3.85 | -2.22 | -6.33 | 0.99 | 1.09 |
| Long Term Debt / Equity (X) | 0.02 | 0.01 | 0.02 | 0.03 | 0.00 |
| Total Debt / Equity (X) | 0.17 | 0.09 | 0.12 | 0.12 | 0.03 |
| Asset Turnover Ratio (%) | 0.62 | 0.53 | 0.41 | 0.30 | 0.35 |
| Current Ratio (X) | 2.05 | 2.40 | 2.49 | 2.99 | 2.72 |
| Quick Ratio (X) | 1.06 | 1.40 | 1.51 | 1.90 | 1.66 |
| Inventory Turnover Ratio (X) | 2.49 | 1.12 | 0.86 | 0.87 | 1.15 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 85.18 | 82.04 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 22.66 | 23.72 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 14.82 | 17.96 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 77.34 | 76.28 |
| Interest Coverage Ratio (X) | 14.27 | 5.82 | -0.40 | 19.70 | 27.60 |
| Interest Coverage Ratio (Post Tax) (X) | 7.54 | 0.43 | -8.45 | 6.59 | 7.77 |
| Enterprise Value (Cr.) | 5189.65 | 3504.16 | 2147.12 | 2049.28 | 2195.83 |
| EV / Net Operating Revenue (X) | 2.46 | 2.06 | 1.60 | 1.61 | 1.78 |
| EV / EBITDA (X) | 17.29 | 26.58 | -304.97 | 17.03 | 15.54 |
| MarketCap / Net Operating Revenue (X) | 2.31 | 2.02 | 1.52 | 1.44 | 1.76 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 14.81 | 17.95 |
| Price / BV (X) | 1.99 | 1.46 | 0.83 | 0.70 | 0.85 |
| Price / Net Operating Revenue (X) | 2.31 | 2.02 | 1.52 | 1.44 | 1.76 |
| EarningsYield | 0.02 | -0.02 | -0.09 | 0.01 | 0.01 |
After reviewing the key financial ratios for Unichem Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 19.53. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.53, marking an increase of 29.54.
- For Diluted EPS (Rs.), as of Mar 25, the value is 19.53. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.53, marking an increase of 29.54.
- For Cash EPS (Rs.), as of Mar 25, the value is 37.23. This value is within the healthy range. It has increased from 6.07 (Mar 24) to 37.23, marking an increase of 31.16.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 348.10. It has increased from 335.54 (Mar 24) to 348.10, marking an increase of 12.56.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 348.10. It has increased from 335.54 (Mar 24) to 348.10, marking an increase of 12.56.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 299.85. It has increased from 242.15 (Mar 24) to 299.85, marking an increase of 57.70.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 42.64. This value is within the healthy range. It has increased from 18.73 (Mar 24) to 42.64, marking an increase of 23.91.
- For PBIT / Share (Rs.), as of Mar 25, the value is 24.95. This value is within the healthy range. It has increased from 2.64 (Mar 24) to 24.95, marking an increase of 22.31.
- For PBT / Share (Rs.), as of Mar 25, the value is 21.96. This value is within the healthy range. It has increased from -8.76 (Mar 24) to 21.96, marking an increase of 30.72.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 19.53. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.53, marking an increase of 29.54.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 19.53. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.53, marking an increase of 29.54.
- For PBDIT Margin (%), as of Mar 25, the value is 14.22. This value is within the healthy range. It has increased from 7.73 (Mar 24) to 14.22, marking an increase of 6.49.
- For PBIT Margin (%), as of Mar 25, the value is 8.31. This value is below the healthy minimum of 10. It has increased from 1.09 (Mar 24) to 8.31, marking an increase of 7.22.
- For PBT Margin (%), as of Mar 25, the value is 7.32. This value is below the healthy minimum of 10. It has increased from -3.61 (Mar 24) to 7.32, marking an increase of 10.93.
- For Net Profit Margin (%), as of Mar 25, the value is 6.51. This value is within the healthy range. It has increased from -4.13 (Mar 24) to 6.51, marking an increase of 10.64.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.51. This value is below the healthy minimum of 8. It has increased from -4.13 (Mar 24) to 6.51, marking an increase of 10.64.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.61. This value is below the healthy minimum of 15. It has increased from -2.98 (Mar 24) to 5.61, marking an increase of 8.59.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.81. This value is below the healthy minimum of 10. It has increased from 0.75 (Mar 24) to 6.81, marking an increase of 6.06.
- For Return On Assets (%), as of Mar 25, the value is 3.85. This value is below the healthy minimum of 5. It has increased from -2.22 (Mar 24) to 3.85, marking an increase of 6.07.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has increased from 0.09 (Mar 24) to 0.17, marking an increase of 0.08.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.62. It has increased from 0.53 (Mar 24) to 0.62, marking an increase of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 2.05. This value is within the healthy range. It has decreased from 2.40 (Mar 24) to 2.05, marking a decrease of 0.35.
- For Quick Ratio (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has decreased from 1.40 (Mar 24) to 1.06, marking a decrease of 0.34.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.49. This value is below the healthy minimum of 4. It has increased from 1.12 (Mar 24) to 2.49, marking an increase of 1.37.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 14.27. This value is within the healthy range. It has increased from 5.82 (Mar 24) to 14.27, marking an increase of 8.45.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.54. This value is within the healthy range. It has increased from 0.43 (Mar 24) to 7.54, marking an increase of 7.11.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5,189.65. It has increased from 3,504.16 (Mar 24) to 5,189.65, marking an increase of 1,685.49.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.46. This value is within the healthy range. It has increased from 2.06 (Mar 24) to 2.46, marking an increase of 0.40.
- For EV / EBITDA (X), as of Mar 25, the value is 17.29. This value exceeds the healthy maximum of 15. It has decreased from 26.58 (Mar 24) to 17.29, marking a decrease of 9.29.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.31. This value is within the healthy range. It has increased from 2.02 (Mar 24) to 2.31, marking an increase of 0.29.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 1.99. This value is within the healthy range. It has increased from 1.46 (Mar 24) to 1.99, marking an increase of 0.53.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.31. This value is within the healthy range. It has increased from 2.02 (Mar 24) to 2.31, marking an increase of 0.29.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.02 (Mar 24) to 0.02, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Unichem Laboratories Ltd:
- Net Profit Margin: 6.51%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.81% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.61% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.54
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.06
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 21.7 (Industry average Stock P/E: 53.07)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.17
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.51%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 47, Kandivli Industrial Estate, Mumbai Maharashtra 400067 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Prakash A Mody | Chairman, Non Ind & Non Exe Director |
| Mr. Pabitrakumar Bhattacharyya | Managing Director |
| Mr. Pranay Godha | Non Exe.Non Ind.Director |
| Ms. Priti Puri | Independent Director |
| Mr. Anand Kusre | Independent Director |
| Mr. Arun Todarwal | Independent Director |
FAQ
What is the intrinsic value of Unichem Laboratories Ltd?
Unichem Laboratories Ltd's intrinsic value (as of 25 December 2025) is 342.48 which is 23.72% lower the current market price of 449.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 3,158 Cr. market cap, FY2025-2026 high/low of 791/432, reserves of ₹2,421 Cr, and liabilities of 3,556 Cr.
What is the Market Cap of Unichem Laboratories Ltd?
The Market Cap of Unichem Laboratories Ltd is 3,158 Cr..
What is the current Stock Price of Unichem Laboratories Ltd as on 25 December 2025?
The current stock price of Unichem Laboratories Ltd as on 25 December 2025 is 449.
What is the High / Low of Unichem Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Unichem Laboratories Ltd stocks is 791/432.
What is the Stock P/E of Unichem Laboratories Ltd?
The Stock P/E of Unichem Laboratories Ltd is 21.7.
What is the Book Value of Unichem Laboratories Ltd?
The Book Value of Unichem Laboratories Ltd is 346.
What is the Dividend Yield of Unichem Laboratories Ltd?
The Dividend Yield of Unichem Laboratories Ltd is 0.00 %.
What is the ROCE of Unichem Laboratories Ltd?
The ROCE of Unichem Laboratories Ltd is 6.24 %.
What is the ROE of Unichem Laboratories Ltd?
The ROE of Unichem Laboratories Ltd is 5.59 %.
What is the Face Value of Unichem Laboratories Ltd?
The Face Value of Unichem Laboratories Ltd is 2.00.